Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma

Cong Peng, Rou-Li Zhou, Gen-Ze Shao, Jing-An Rui, Shao-Bin Wang, Ming Lin, Sha Zhang, Zi-Feng Gao

AIM: To produce high-quality polyclonal antibody to lysosome-associated protein transmembrane 4B-35 and to identify LAPTM4B-35 expression in cancer tissues and its correlation with differentiation status of hepatocellular carcinoma (HCC).

METHODS: The 297 bp 5' end of LAPTM4B cDNA was obtained by PCR and inserted into prokaryotic expression vector pGEX-KG. Then the recombinant pGEX-KG-N1-99 was transformed into E. coli JM109 to express GST-fusion protein. The fusion protein was purified by glutathione sepharose 4B agarose. The purified GST-LAPTM4B-N1-99 was characterized by SDS-PAGE, and used to immunize rabbits. The titer and specificity of antisera were detected by ELISA and Western blot, respectively. The correlation between the expression levels of LAPTM4B-35 and the differentiation status of HCC was analyzed via Western blot. The expression of LAPTM4B-35 in HCC and other six cancer tissues was investigated via tissue chip and immunohistochemical analysis.

RESULTS: About 6.2 mg of pure GST-LAPTM4B-N1-99 was isolated from 1 L of bacteria. The GST-LAPTM4B-N1-99 produced high titer antisera in rabbits and showed good immunity. Western blot showed specific reactions for the antibody to the LAPTM4B-35 in the total proteins from HCC tissues and BEL-7402 cells, also to the fusion protein purified or in the transformed bacteria. LAPTM4B-35 was remarkably expressed in several cancers, such as HCC, breast cancer, gastric carcinoma, lung cancer, and colon carcinoma, but not commonly expressed in esophageal cancer and rectum carcinoma. Notably, the expression levels of LAPTM4B-35 were significantly and inversely correlated to the differentiation of HCCs in a 20 case analysis.

CONCLUSION: Specific polyclonal antibody (LAPTM4B-N1-99-pAb) to LAPTM4B-35 was produced. It identified the expression of LAPTM4B-35 in some cancer tissues originated from single layer cuboidal and columnar epithelial cells and firmly demonstrated that the expression of LAPTM4B-35 in HCC was inversely correlated with the differentiation of HCC.

Key words: LAPTM4B; LAPTM4B-N1-99-pAb; HCC; Tissue microarray

INTRODUCTION

Hepatocellular carcinoma (HCC) remains one of the commonest internal malignancies of mankind. It ranks fifth in frequency in the world with an estimated number of 0.5-1 million cases per year, most of which occur in sub-Saharan Africa and south-east Asia including China. The vast majority can be attributed to chronic hepatitis B virus (HBV) infection and there has been almost no change in incidence. It has also become evident that the number of HCC is increasing in low to middle-incidence countries such as USA[4-6], France[7,8], UK[9,10] and Japan[11,12]. The rising number of cases in these countries is most likely to be due to chronic hepatitis C virus (HCV) infection[13,14]. LAPTM4B, which was first cloned by our research group as a novel oncogene candidate, is highly expressed in vast majority of HCCs[13,14]. BLAST program analysis showed that the LAPTM4B was mapped to chromosome 8q22.1, the gain region in HCC shown by CGH analysis. The ORF of LAPTM4B contains two ATGs, indicating that this gene may encode two putative proteins with 35 kDa (317 aa) and 24 kDa (226 aa)[15,16], respectively. The former study confirmed that the LAPTM4B-35 was translated from the whole ORF and initiated from the first ATG, whereas the LAPTM4B-24 was translated from the second ATG[15]. The integral membrane protein characteristics were indicated by computer
gene was widely expressed in normal human tissues shown by Northern blot[14]. Its expression was high in heart, skeletal muscle and testis; moderate in ovary, kidney; and pancreas; low in liver, spleen, and thymus; but lowest in lung and peripheral leukocytes. It was remarkably overexpressed (48 over 55 cases) in HCC when compared with PNL. Furthermore, the expression levels of LAPTMB4 mRNA were significantly related to the differentiation status of HCCs: the highest in poorly-differentiated HCCs, higher in moderately-differentiated HCCs, and low in well-differentiated HCCs[14].

The biological effects of LAPTMB4 were studied by transient and stable transfection. The result showed that cell proliferation was promoted via LAPTMB4 stable transfection of both mouse NIH3T3 cells[16] and human HEL cells (manuscripts in preparation). Also, the LAPTMB4 transfected NIH3T3 cells were tumorigenic when the transfectants were inoculated into NIH mice. Immunoprecipitation assay indicated that LAPTMB4 interacted with integrin-αβ1 in BEL-7402 cells, which were enhanced by LN-1[10], and might play an important role in the integrin-αβ6 mediating signal transduction pathways. It was also found that the sequences of 91 amino acids at the N-terminus of LAPTMB4-35 were essential for its functions on cell survival and growth, which was revealed via transient transfection of plasmids containing full length and truncated sequences (273 bp) at the 5' end of LAPTMB4 ORF into HEL cells[14]. After 2-3 wk of G418 selection, colonies in pCDNA3-BE (containing truncated ORF) transfected cells were almost completely disappeared, whereas the pCDNA3-AE (containing full ORF) transfected cells formed lots of colonies[14]. These results indicate that LAPTMB4-35 plays an important role in the regulation of cell survival, proliferation, and may involve in carcinogenesis.

It was evidenced that the overexpression of LAPTMB4-35 promoted malignant transformation of some cell lines, including accelerated proliferation, migration and invasion of cells, and activated some protooncogenes, including immediate early genes, such as c-myc, c-fos and c-jun (manuscripts preparation).

To investigate the function and expression of LAPTMB4-35 in HCC and HCC cell lines, specific antibody to LAPTMB4-35, but not LAPTMB4-24, the 297 bp at 5' end of LAPTMB4 cDNA encoding LAPTMB4-N1-99 was cloned into donor vector pGEX-KG[17-19] and the recombinant plasmid was transformed into competent E. coli cells JM109. The GST-LAPTMB4-N1-99 fusion protein was produced in JM109 cells after induced with IPTG, and purified using glutathione sepharose 4B agarose[20-21]. After rabbits were immunized, specific polyclonal antibodies, LAPTMB4-N1-99-pAb, against the N-terminus of LAPTMB4-35 were obtained. With this antibody, the expressions of LAPTMB4-35 in HCC and several cancer tissues were performed via Western blot and TMA[20-24], respectively. The correlation between expression levels of LAPTMB4-35 and HCC differentiation status were analyzed.

MATERIALS AND METHODS

Subjects

A total of 20 pairs of specimens were obtained from patients with HCC (aged from 35 to 70 years) who underwent hepatectomy at the Peking Union Medical College Hospital (the West Hospital) in Beijing. Histopathological analyses were independently performed by pathologists. Tumor differentiation was graded as I-III, according to the Edmondson Grading System[25,26]. Specimens were frozen immediately after surgical resection and stored in liquid nitrogen.

Chemicals

Molecular biological enzymes were purchased from Sangon Biotechnology Ltd. Peroxidase-conjugated goat anti-rabbit IgG (H+L) was purchased from Zhongshan Biotechnology Ltd. Glutathione-sepharose 4B agarose was purchased from Pharmacia Biotech Ltd.

Tissue microarray (TMA)

A TMA slide was purchased from Chengdu Phargentech Ltd. It contained 60 species of tissues, including two normal esophageal epithelial and eight esophageal cancer tissues, two normal mammary gland and eight breast cancer tissues, two normal lung and eight lung cancer tissues, two normal gastric epithelial and eight gastric carcinoma tissues, two normal colononic epithelial and eight colon carcinoma tissues, two normal rectal epithelial and eight rectum carcinoma tissues. All specimens were embedded in paraffin.

Cloning of LAPTMB4 cDNA encoding LAPTMB4-N1-99

To clone the 5' end of LAPTMB4 ORF, PCR method was used. Based on the published LAPTMB4 gene sequence[16], two oligonucleotide primers (P1: 5' GGAGATCCGGCACCACAGTACGGCGACTCGG 3'; P2: 5' GGAGATTCTTCCAGGGCGGACCATCG 3') were synthesized (Sangon Biotechnology Ltd). P1 was extended to the 5'end containing recognition sequences for endonuclease BamHI (underlined). P2 was extended to the 5'end containing recognition sequences for endonuclease HindIII(underlined). PCR amplification was performed for 30 cycles at 94 °C for 30 s, at 55 °C for 30 s and at 72 °C for 50 s.

Expression vector construction

The pGEX-KG vector was digested with BamHI and HindIII. cDNA fragment at the 5' end of LAPTMB4 ORF was subcloned into the corresponding site of pGEX-KG to obtain a plasmid pGEX-KG-N1-99. Then the recombiant plasmid was transformed into the E.coli strain JM109. The transformed colonies containing the cloned cDNA were screened by restriction enzyme analysis and DNA sequencing.

Expression and purification of GST-LAPTMB4-N1-99 in E.coli

An overnight LB culture of E.coli containing pGEX-KG-N1-99 was inoculated at a dilution of 1:100, and incubated at 37 °C with shaking. When the absorbance at 600 nm reached 0.6, GST-LAPTMB4-N1-99 expression was induced by the addition of 0.5 mmol/L IPTG. Further 4 h for growing, the E.coli strains were harvested by spinning at 4 000 r/min for 15 min at 4 °C. The pellet was resuspended in PBS containing 0.05% Tween-20 of the original volume and lysed by sonication on ice, and then centrifuged at 10 000 g for 20 min at 4 °C. The supernatant was passed through glutathione-sepharose 4 B beads according to the manufacturer's instructions. SDS-PAGE was performed to analyze the purified protein from the infected cells.
**Immunogenicity assay on recombinant protein**

Two rabbits were used to generate polyclonal antibodies against the fusion protein. Each rabbit was injected with 1 mg purified fusion protein in complete adjuvant in the initial injection and with incomplete adjuvant for the following injection. Before injection, the rabbit blood was collected for producing pre-immune serum. The titer of antisera was measured by ELISA.

**Western blot**

Proteins in cell lysates and tissues were fractionated by 10% SDS-PAGE and followed by electrotransferring onto nitrocellulose filters (Bio-Rad). The filters were blocked at 4 °C overnight with a blocking buffer (pH 7.6) containing 5% non-fat dry milk. Then the filters were incubated with indicated antibody (1:300) for 2 h at room temperature. After being washed with TBST (pH 6.0), the filters were incubated at room temperature for 1 h with horseradish peroxidase conjugated goat anti-rabbit IgG at 1:2,000 dilution in TBS-0.5% non-fat dry milk. Immunoreactive bands were visualized using ECL detection reagents (Santa Cruz).

**Immunohistochemistry**

HCC tissue and TMA slide were fixed in 4% PFA in PBS for 10 min, washed twice with PBS, and incubated in 3% HCC tissue and TMA slide were fixed in 4% PFA in PBS. Immunohistochemistry was visualized using ECL detection reagents (Santa Cruz).

**RESULTS**

**Expression of fusion protein and protein purification**

Confirmed by restriction endonuclease digestion and DNA sequencing, pGEX-KG-N199 plasmid was successfully constructed and GST-LAPTMB4-N199 was expressed in E.coli JM109 by IPTG induction. A 36 kDa fusion protein was stained in high intensity by 10% SDS-PAGE (Figure 1). This fusion protein was majored as a soluble pattern.

**Figure 1** Purification of GST-LAPTMB4-N199. 1: Uninduced pGEX-KG-N199/JM109; 2: induced pGEX-KG-N199/JM109; 3: supernatant of induced pGEX-KG-N199/JM109; 4: eluted fragment of glutathione sepharose4B column; 5: eluted by PBS; 6: purified fusion protein GST-LAPTMB4-N199.

**Titer and specification of LAPTMB4-N199-pAb**

After being immunized thrice with purified GST-LAPTMB4-N199, two rabbits both generated antibodies at a titer of 5×10^4, measured by ELISA. Western blot analysis showed that there was a specific Ag-Ab binding band at 36 kDa in the unpurified and purified GST-LAPTMB4-N199 (Figure 2A, lanes 1 and 2). The BEL-7402 cell lysate was also identified by LAPTMB4-N199-pAb (Figure 2B, lane 4).

**Figure 2** Western blot analysis of the specificity of LAPTMB4-N199-pAb. 1: pGEX-KG-N199/JM109 induced with IPTG (36 ku); 2: Purified infused protein (36 ku); 3: pGEX-KG-N199 JM109 induced without IPTG; 4: BEL-7402 cell lysis, Western blot by LAPTMB4-N199-pAb; 5: BEL-7402 cell lysis, Western blot by preimmunized antiserum.

**Expression analysis of LAPTMB4-35 in HCC**

The expression levels of LAPTMB4-35 were significantly related to the differentiation status of HCCs: highest in poorly-differentiated HCCs (grade III, 12/20), high in moderately-differentiated HCCs (grade II, 4/20), and low in well-differentiated HCCs (grade I, 4/20) (Figure 3).

**Immunohistochemical analysis of LAPTMB4-35 on HCC tissue and TMA**

Immunohistochemical analysis was undertaken to characterize the expression of LAPTMB4-35 in HCC and TMA. In HCC (Figure 4A), positive brown signals were seen only in HCC cells and negative signals in the interstitial tissue of liver. The result was well coincident with the mRNA detection via in situ hybridization (Figure 4C)\[14\]. Moreover, the expression of LAPTMB4-35 was also analyzed via TMA in six types of cancer tissues: esophageal carcinoma, breast cancer, pulmonary carcinoma, gastric carcinoma, colon carcinoma,
and rectum carcinoma. There were no significant LAPTM4B-35 expressions in six counterparts of normal tissues but obvious high and weak expression accounted for the majority of breast cancers and gastric carcinomas. Positive staining could only be observed in minority of pulmonary carcinomas and colon carcinomas and almost negative staining in all of esophageal carcinomas and rectum carcinomas tested (Figure 5).

Figure 4 Analysis of LAPTM4B-35 and LAPTM4B mRNA expression by ISH in HCCs. A: immunized antisera (20×); B: preimmunized antisera (20×); C: LAPTM4B mRNA expression in HCCs (20×); D: paired noncancerous tissue (20×).

Figure 5 Analysis of LAPTM4B via TMA. A: Scores assigned to each tissue spot according to three different staining coverages. Negative represents the complete negative staining. Weak represents scores assigned to tissue disks with borderline and partial positive staining. The complete positive staining was designated as strong; B: Representative elements of a TMA stained with LAPTM4B-N1-99-pAb. Magnification ×200. Normal tissue stained with LAPTM4B-N1-99-pAb (A1: esophageal mucous; B1: mammary gland tissue; C1: normal lung tissue; D1: gastric mucous; E1: colonic mucous; F1: rectal mucous). Tumor tissue stained with LAPTM4B- N1-99-pAb (A2: esophageal carcinoma; B2: breast cancer; C2: pulmonary carcinoma; D2: gastric carcinoma; E2: colon carcinoma; F2: rectal carcinoma); C: Histogram of LAPTM4B expression assessed using 6 TMAs.
DISCUSSION

In our previous work, we have produced a polyclonal antibody: LAPTMB4-EC2-pAb, which was prepared by immunization with KLH-conjugated 10-peptides whose sequences are localized at the second extracellular loop between the third and fourth transmembrane regions. By Western blot, expressions of LAPTMB4-35 and LAPTMB4-24 were identified in HCC, PNL and NL tissues with LAPTMB4-EC2-pAb, indicating that LAPTMB4-35 may initiate from the first ATG, whereas LAPTMB4-24 is translated from the second ATG. Notably, the expression levels of LAPTMB4-35 were primarily shown by Western blot with LAPTMB4-EC2-pAb to correlate with the differentiation status of 12 cases of HCC tissues, but the expression levels of LAPTMB4-24 did not relate to the differentiation status of HCC tissues.

To further clarify the correlation between upregulation of LAPTMB4-35 and differentiation of HCC and the function of LAPTMB4-35, we generated a specific antibody: LAPTMB4-N1099-pAb, against LAPTMB4-35 but not against LAPTMB4-24. Applying this antibody, it was firmly demonstrated that the expression of LAPTMB4-35 protein was inversely related with the status of differentiation status of HCC, suggesting its importance in carcinogenesis and progress of HCC as well as a possibility of being a criterion of HCC differentiation and pathological grading. The expression levels of LAPTMB4-35 were not found to correlate with the AFP levels of sera.

Using LAPTMB4-N1099-pAb, the expression of LAPTMB4-35 in some cancers originated from single layer cuboidal and columnar epithelia, such as HCC, breast cancer, gastric cancer and pulmonary cancer. We have previously reported that the high metastatic cell lines, such as the giant cell pulmonary carcinoma and prostate carcinoma cell lines highly expressed LAPTMB4-35. However, cancers originated from stratified epithelium, such as esophageal carcinoma and rectum carcinoma, did not practically express LAPTMB4-35. Malignant tumors from mesenchymal cells did not express LAPTMB4-35 either. The result of TMA gave us a clue that LAPTMB4-35 might also play an important role in breast cancer, gastric cancer or pulmonary carcinoma.

In conclusion, specific polyclonal antibody to the cytoplasmic N-terminal tail of LAPTMB4-35 was obtained and used for Western blot and immunohistochemistry. The expression of LAPTMB4-35 is associated with the differentiation status of HCC. In addition, the expression of LAPTMB4-35 in other cancer tissues may pave the way for further study on the function of N-terminal of LAPTMB4-35 for the development of tumors and their clinical diagnosis.

REFERENCES

1. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Companibility and quality of data. IARC Sci Publ 1992; 45-173
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285
3. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
5. Kaczynski J, Oden A. The rising incidence of hepatocellular carcinoma. N Engl J Med 1999; 341: 451; author reply 452
6. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999; 340: 790-799
7. Benhamiche AM, Faivre C, Minello A, Clinar F, Mitry E, Hillon P, Faivre J. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J Hepatol 1998; 29: 802-806
8. Deuffic S, Buffat L, Poyeard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-1601
9. Mant JW, Vessey MP. Trends in mortality from primary liver cancer in England and Wales 1975-92: influence of oral contraceptives. Br J Cancer 1995; 72: 800-803
10. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Incidence in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143
11. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-4972
12. Makimoto K, Higuchi S. Alcohol consumption as a major risk factor for the rise in liver cancer mortality rates in Japanese men. Int J Epidemiol 1999; 28: 30-34
13. Liu J, Zhou R, Zhang N, Rui J, Jin C. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 2000; 113: 881-885
14. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X, Ye DX. Molecular cloning and characterization of LAPTMB4, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003; 22: 5060-5069
15. Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, Zhang S, Lin M, Rui J, Ye D. Identification and characterization of LAPTMB4 encoded by a human hepatocellular carcinoma-associated novel gene. Beijing Daxue Xuebao 2003; 35: 340-347
16. He J, Shao G, Zhou R. Effects of the novel gene, LAPTMB4, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells. Beijing Daxue Xuebao 2003; 35: 348-352
17. Hakes DJ, Dixon JE. New vectors for high level expression of recombinant proteins in bacteria. Anal Biochem 1992; 202: 293-298
18. Guan KL, Dixon JE. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal Biochem 1991; 192: 262-267
19. Ball EH, Shepard LB, Gill GN. Purification and properties of thyroid hormone receptor beta 1 expressed in Escherichia coli as a fusion protein. Protein Expr Purif 1995; 6: 33-38
20. Corsaro A, Thellung S, Russo C, Villia V, Arena S, D’Adamo MC, Paludi D, Rossi Principe D, Damonte Ginetti D, Tramonti S, Arasi D, Tagliavini F, Schettini G, Florio T. Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein. Neurochem Int 2002; 41: 55-63
21. Mercado-Pimentel ME, Jordan NC, Aisemberg GO. Affinity purification of GST fusion proteins for immunohistochemical studies of gene expression. Protein Expr Purif 2002; 26: 260-265
22. Hewitt SM. Design, construction, and use of tissue microarrays. Methods Mol Biol 2004; 264: 61-72
23. Zhang DH, Salto-Tellez M, Chiu LL, Shen L, Koay ES. Tissue microarray study for classification of breast tumours. Ann Acad Med Singapore 2003; 32: S75-S76
24. Otsuka M, Kato M, Yoshikawa T, Chen H, Brown EJ, Masuho Y, Omata M, Seki N. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem Biophys Res Commun 2001; 289: 876-881
25. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987; 7: 18-26
26. Sasaki Y, Imaoka S, Ishiguro S, Nakano H, Kasugai H, Fujita M, Inoue E, Ishikawa O, Furukawa H, Nakamori S, Kuroda C, Iwanaga T. Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery 1996; 119: 252-260